| --- | --- | --- | |----------------------------|-------|-------| | | | | | | | | | | | | | Q2 2022 Financial Results | | | | Presentation August 2,2022 | | | | | | | 1 Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1955 ("PSLRA") relating to, among other things, Rigel's licensing agreement with Forma Therapeutics Holdings, Inc. ("Forma Therapeutics") and the success thereof; Rigel's ability to successfu ...